Overview
On 29 May 2019, orphan designation (EU/3/19/2160) was granted by the European Commission to RHEACELL GmbH & Co. KG, Germany, for allogeneic skin-derived ABCB5-positive mesenchymal stem cells (also known as allo-APZ2-EB) for the treatment of epidermolysis bullosa.
Key facts
Active substance |
Allogeneic skin-derived ABCB5-positive mesenchymal stem cells
|
Intended use |
Treatment of epidermolysis bullosa
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2160
|
Date of designation |
29/05/2019
|
Sponsor |
RHEACELL GmbH & Co. KG |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: